In the current work, new thiazolyl-pyrazoline derivatives were synthesized and investigated for their in vitro inhibitory effects on AChE and BuChE. Moreover, the compliance of the compounds to the Lipinski's rule of five was evaluated. Naphthalenesubstituted compound 3g was the most potent AChE inhibitor (38.5±2.85%), whereas u n c o r r e c t e d p r o o f fluoro-substituted compound 3c was the most effective BuChE inhibitor (43.02±2.71%) in this series. In the view of this work, the structural modification of the identified compounds are on-going for the generation of new anticholinesterase agents with enhanced efficacy and selectivity.
INTRODUCTION
Alzheimer's disease (AD), a progressive multifarious neurodegenerative disorder, is the leading cause of dementia in elderly people all over the world. The incidence of AD is predicted to increase dramatically in the future, as the average age of the population increases. Although extensive efforts have been devoted to the discovery of anti-AD drugs for almost a century, donepezil, galantamine, rivastigmine (cholinesterase inhibitors) and memantine (N-methyl-D-aspartate receptor antagonist) are the only drugs currently used for the management of AD. These agents only provide symptomatic relief but do not halt the progression of the disease. [1] [2] [3] [4] [5] Development of new potent anti-AD drugs is a difficult and time-consuming process, and many molecules reaching clinical trials simply fail. Most phase II clinical trials ending with a positive outcome do not succeed in phase III, often due to serious adverse effects or lack of therapeutic efficacy. 6, 7 Acetylcholinesterase (AChE) is a highly viable target for the design and development of potent anti-AD agents due to its role in the pathogenesis of AD. [1] [2] [3] [4] [5] [6] [7] [8] On the other hand, in progressed AD, the level of AChE in brain declines to 55-67% of normal values, whereas butyrylcholinesterase (BuChE) increases to 120% of normal levels, indicating that BuChE plays a pivotal role for acetylcholine (ACh) hydrolysis in the late stage of AD. As a result, selective inhibition of BuChE has emerged as a promising therapeutic approach to elevate ACh level in progressed AD. 9, 10 Thiazole has been recognized as a promising scaffold for the design and development for central nervous system (CNS) active agents. There are thiazole-based CNS drugs currently used as therapeutic agents for the treatment of various CNS disorders and a number of thiazole derivatives are in clinical trials. 11 -14 Acotiamide has been reported to be a promising thiazole-based agent for the treatment of functional dyspepsia in clinical trials. Acotiamide enhances ACh release in the enteric nervous system through AChE inhibition and M1/M2 muscarinic receptor antagonism. 15 Pyrazoline has also attracted a great deal of interest as an indispensable scaffold due to its diverse therapeutic applications extending from CNS applications to antimicrobial therapy. 16, 17 Diversely substituted pyrazolines embedded with a variety of functional groups have been reported to inhibit MAOs and cholinesterases, molecular targets important for the treatment of neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease. [16] [17] [18] [19] [20] [21] [22] [23] Prompted by the aforementioned findings and in the continuation of our ongoing research on thiazoles 24 and pyrazolines 25 as cholinesterase inhibitors, herein we designed a new series of thiazolyl-pyrazoline derivatives based on molecular hybridization of thiazole and pyrazoline scaffolds 26 . A facile and versatile synthetic route was used to prepare the title compounds and their inhibitory effects on AChE and BuChE were investigated. A computational study for the prediction of ADME properties of all compounds was also performed.
MATERIALS AND METHODS

Chemistry
All reagents were purchased from commercial suppliers and were used without further purification. Melting points (M.p.) were determined on an Electrothermal 9100 melting point apparatus (Weiss-Gallenkamp, Loughborough, UK). 
1-(2-Furanyl)-3-(1,3-benzodioxol-5-yl)-2-propen-1-one (1)
A mixture of 2-acetylfuran (0.06 mol), 1,3-benzodioxole-5-carboxaldehyde (0.06 mol) and 40% (w/v) sodium hydroxide (10 mL) in ethanol (30 mL) was stirred at room temperature for about 24 h. The resulting solid was washed, dried, and crystallized from ethanol.
27,28
3-(2-Furanyl)-5-(1,3-benzodioxol-5-yl)-1-thiocarbamoyl-4,5-dihydro-1H-pyrazole (2)
A mixture of compound 1 (0.03 mol), thiosemicarbazide (0.036 mol) and sodium hydroxide (0.075 mol) was refluxed in ethanol (30 mL) for 12 h. The product was poured into crushed ice. The precipitate was filtered and crystallized from ethanol. 29 
2-[5-(1,3-benzodioxol-5-yl)-3-(furan-2-yl)-4,5-dihydro-1H-pyrazol-1-yl]-4-(aryl)thiazole (3a-g)
A mixture of compound 2 (0.01 mol), substituted aryl acyl bromide (0.01 mol) in ethanol (20 mL) was refluxed for 10 h. After cooling, the precipitate was collected by suction filtration. The product was crystallized from ethanol. 29 
2-[5-(1,3-Benzodioxol-5-yl)-3-(furan-2-yl)-4,5-dihydro-1H-pyrazol-1-yl]-4-(4-(methylsulfonyl)phenyl)thiazole (3a)
Yield 
2-[5-(1,3-Benzodioxol-5-yl)-3-(furan-2-yl)-4,5-dihydro-1H-pyrazol-1-yl]-4-(4-(trifluoromethyl)phenyl)thiazole (3b)
Yield: 80%; M.p. 77-78 °C.
u 
2-[5-(1,3-Benzodioxol-5-yl)-3-(furan-2-yl)-4,5-dihydro-1H-pyrazol-1-yl]-4-(4-fluorophenyl)thiazole (3c)
Yield: 81%; M.p. 89-90 °C. 
2-[5-(1,3-Benzodioxol-5-yl)-3-(furan-2-yl)-4,5-dihydro-1H-pyrazol-1-yl]-4-(2,5-dimethoxyphenyl)thiazole (3e)
Yield
2-[5-(1,3-Benzodioxol-5-yl)-3-(furan-2-yl)-4,5-dihydro-1H-pyrazol-1-yl]-4-[4-(morpholin-4-yl)phenyl]thiazole (3f)
2-[5-(1,3-Benzodioxol-5-yl)-3-(furan-2-yl)-4,5-dihydro-1H-pyrazol-1-yl]-4-(naphthalen-
2-yl)thiazole (3g)
Determination of AChE and BuChE Inhibitory Activity
The inhibitory effects of compounds 3a-g on AChE and BuChE were determined by were added, and the final mixture was incubated at room temperature for 30 min. Blank was prepared using 10 μL of DMSO instead of the test sample, with all other procedures similar to those used in the case of the sample mixture. Absorbances were measured at 412 nm and 37 °C using polystyrene cuvettes with spectrophotometer (UV-1700, Shimadzu). Experiment was done in triplicate. Galantamine was used as a positive control. Data are expressed as mean ± standard deviation (SD). The inhibition (percent) of AChE or BuChE was calculated using the following equation: I (%) = 100 − (ODsample / ODcontrol) × 100
In silico Prediction of ADME Parameters
The physicochemical parameters (log P, TPSA, nrotb, molecular weight, number of hydrogen bond donors and acceptors, molecular volume) of compounds 3a-g were calculated using Molinspiration software.
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RESULTS AND DISCUSSION
The synthesis of thiazole derivatives (3a-g) followed the general pathway outlined in The inhibitory effects of compounds 3a-g on AChE and BuChE were determined by a modification of Ellman's spectrophotometric method (Table 1) . Galantamine was used as a positive control. According to the results, compounds 3a-g showed less ChE inhibitory activity than galantamine.
Compounds 3a, 3b, 3e, 3f and 3g showed less than 50% AChE inhibition at 80 µg/mL, whereas compounds 3c and 3d did not show any inhibitory activity against AChE.
Compound 3g was identified as the most potent AChE inhibitor (38.5±2.85%) in this series. This outcome indicated that naphthalene ring enhanced the inhibitory activity against AChE. The increased activity can be attributed to its high lipophilicity due to the presence of naphthalene moiety.
Compounds 3a, 3f and 3g did not show any inhibitory activity against BuChE, whilst the other compounds showed BuChE inhibitory activity ranging from 43.02 to 21.44%.
The most selective BuChE inhibitor was found as compound 3c (43.02±2.71%) followed by compound 3d (38.52±3.33%). This outcome pointed out the importance of fluoro substituent for BuChE inhibitory activity. As a part of this study, Molinspiration software was used to determine their physicochemical parameters (log P, TPSA, nrotb, molecular weight, number of 
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According to in silico studies, compound 3b, 3c, 3d, 3e and 3g only violated one parameter of Lipinski's rule of five, whereas compound 3a did not violate Lipinski's rule (Table 2) . On the basis of Lipinski's rule of five, they were expected to have good oral bioavailability. On the other hand, compound 3f violated two parameters of Lipinski's rule of five, and therefore it can be concluded that compound 3f may have bioavailability problems. 
